Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382016 · ClinicalTrials.gov registry record · Phase 4
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
A Phase 4 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 4
- Development phase
- 85
- Enrollment target
NCT02382016: Completed Phase 4 study, sponsored by Actelion.
NCT02382016 is a Phase 4 study that has completed, run by Actelion. The registered enrollment target is 85 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02382016, a Phase 4 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 85 participants
- Enrollment target
Study Summary
24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
Primary Outcome
The relative change from baseline to Week 12 in PVR is expressed as a ratio of Week 12 to baseline PVR.
Interventions
- OTHER Placebo
- DRUG Macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2015-06-23 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 4 |
What the finished NCT02382016 record still lists
NCT02382016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02382016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02382016 about?
NCT02382016 is a clinical study titled "PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial". 24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
What is the current status of trial NCT02382016?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2015-06-23. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT02382016?
The interventions under investigation include: Placebo (OTHER), Macitentan (DRUG).
Who is sponsoring clinical trial NCT02382016?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02382016's enrollment target sits among peer trials
85 928th of 2000 higher than 1,072 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI